Journey Medical (Journey Medical) Gross Margin % : 60.58% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Journey Medical's Gross Profit for the three months ended in Dec. 2023 was $9.24 Mil. Journey Medical's Revenue for the three months ended in Dec. 2023 was $15.26 Mil. Therefore, Journey Medical's Gross Margin % for the quarter that ended in Dec. 2023 was 60.58%.

The historical rank and industry rank for Journey Medical's Gross Margin % or its related term are showing as below:

DERM' s Gross Margin % Range Over the Past 10 Years
Min: 49.18 Med: 66.33 Max: 69.84
Current: 66.33

During the past 5 years, the highest Gross Margin % of Journey Medical was 69.84%. The lowest was 49.18%. And the median was 66.33%.

DERM's Gross Margin % is ranked better than
81.09% of 989 companies
in the Drug Manufacturers industry
Industry Median: 46.54 vs DERM: 66.33

Journey Medical had a gross margin of 60.58% for the quarter that ended in Dec. 2023 => Durable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Journey Medical was 0.00% per year.

Journey Medical Gross Margin % Historical Data

The historical data trend for Journey Medical's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Gross Margin % Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross Margin %

69.84

67.23

49.18

58.23

66.33

Journey Medical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross Margin %	Get a 7-Day Free Trial											51.66	47.20	54.77	81.39	60.58

Competitive Comparison of Journey Medical's Gross Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical's Gross Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Journey Medical's Gross Margin % falls into.

Journey Medical Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Journey Medical's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )	=	Gross Profit (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	52.5	/	79.181
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(79.181 - 26.66)	/	79.181
	=	66.33 %

Journey Medical's Gross Margin for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )	=	Gross Profit (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	9.2	/	15.257
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	(15.257 - 6.015)	/	15.257
	=	60.58 %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

Journey Medical (NAS:DERM) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Journey Medical had a gross margin of 60.58% for the quarter that ended in Dec. 2023 => Durable competitive advantage

Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.

Journey Medical Gross Margin % Related Terms

Thank you for viewing the detailed overview of Journey Medical's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Journey Medical (Journey Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Gross Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.

Executives

Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135